Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Amr Lexington

Neither a doctor nor a teaching hospital

Research payments

$1,849,947

165 payments

Through program year 2025, Amr Lexington is reported as receiving $1,849,947 in research payments, across 165 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $235,238 120
2024 Research $50,901 7
2023 Research $67,226 8
2022 Research $307,714 5
2021 Research $1,188,868 25

Breakdown

Who paid Research payments · program years 2021–2025
  1. Valneva Austria GmbH $1,188,868 25 payments
  2. Merck Sharp & Dohme Corporation $341,105 5 payments
  3. Vertex Pharmaceuticals Incorporated $246,350 4 payments
  4. Boehringer Ingelheim International GmbH $43,022 116 payments
  5. ACADIA Pharmaceuticals Inc $16,646 3 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $13,526 10 payments
  7. Pfizer Inc. $404 1 payment
  8. Moderna TX, Inc. $26 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study to Evaluate Safety and Immunogenicity of A Live-Atteuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $1,111,980 16 payments
  2. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. $341,105 5 payments
  3. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $187,946 3 payments
  4. A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy $58,405 1 payment
  5. A Randomized, Double-Blinded Phase 3 Study to Demonstrate Lot-To-Lot Consistency of Three Lots of A Live-Attenuated Chikungunya Virus Vaccine Candidate (Vla1553) in Healthy Adults Aged 18 to 45 Years $40,518 6 payments
  6. An Open-Label, Single Arm Study to Evaluate Antibody Persistence and Long Term Safety of A Live-Attenuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $36,370 3 payments
  7. Phase III efficacy for obesity - without T2DM $21,671 3 payments
  8. Acp-044-005 $16,646 3 payments
  9. A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes $9,252 75 payments
  10. phase III efficacy for obesity with T2DM $8,831 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record